Mecamylamine

Mecamylamine is a non-selective, non-competitive antagonist at the nicotinic acetylcholine receptor, also known as a nicotinic antagonist. It was originally used as an antihypertensive agent in the 1950s. Mecamylamine has been used in research to help understand the involvement of nicotinic receptors in the brain.

History[edit | edit source]

Mecamylamine was first synthesized in the early 1950s. It was initially used as an antihypertensive agent, but its use declined with the introduction of more effective and safer treatments. In the 1980s, mecamylamine was found to have effects on the central nervous system, leading to its use in research.

Pharmacology[edit | edit source]

Mecamylamine works by blocking the effects of acetylcholine at nicotinic receptors in the brain. These receptors are involved in a variety of functions, including muscle movement, heart rate, memory, and pain perception. By blocking these receptors, mecamylamine can alter these functions.

Clinical uses[edit | edit source]

While mecamylamine is no longer commonly used as an antihypertensive, it has found use in research and in the treatment of certain disorders. It has been used in the treatment of Tourette's syndrome, nicotine addiction, and certain types of depression.

Side effects[edit | edit source]

Common side effects of mecamylamine include dry mouth, blurred vision, and constipation. More serious side effects can include hallucinations, confusion, and severe abdominal pain.

Research[edit | edit source]

Mecamylamine has been used in research to help understand the role of nicotinic receptors in the brain. It has also been used in studies looking at the treatment of various disorders, including nicotine addiction and depression.